Illumina’s CEO Jacob Thaysen shares highlights from the company’s ‘Strategy Update' today and his vision for the business going forward

blonca9
Aug 13, 2024
1 min read

Jacob Thaysen covers Illumina’s business today, including the NovaSeq X platform, multiomics, clinical and pharma industry applications, and his case for getting Illumina back to financial growth in the years ahead.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Illumina’s CEO Jacob Thaysen shares highlights from the company’s ‘Strategy Update' today and his vision for the business going forward

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight